DXR

Daxor Corporation · NASDAQ

Sector Miscellaneous
Industry Investment Trusts/Mutual Funds
Website daxor.com
Employees(FY) -
ISIN US2394671034

Performance

+5.26%

+3.97%

+9.61%

-4.09%

-3.29%

YTD

+13.5%

Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Advanced Technical Analysis

Technical Analysis of DXR 2024-11-22

The stock exhibits a strong bullish sentiment, highlighted by a Moving Average Score of 96, indicating robust upward momentum, complemented by a Technical Score of 80. While the Oscillators Score of 63 suggests some potential consolidation, the overall indicators point towards a favorable outlook for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of DXR

Stock Rank

Recent News & Updates

2024-10-08 20:00
DAXOR'S INNOVATIVE BVA-100 BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24(Globenewswire)
2024-10-07 20:00
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-27 05:00
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device(Globenewswire)
2024-09-18 20:00
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024(Globenewswire)
2024-09-11 20:00
Newly Published Review Highlights the Pivotal Role of Daxor's Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management(Globenewswire)
2024-09-04 20:00
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee(Globenewswire)
2024-09-03 20:30
Leading Central Florida Hospital Implements Daxor's BVA-100 Blood Volume Diagnostic for Heart Failure Patient Care(Globenewswire)
2024-09-03 04:05
Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter(Globenewswire)
2024-09-03 00:15
Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-28 20:00
Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network(Globenewswire)
2024-08-05 20:00
Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer(Globenewswire)
2024-08-04 20:00
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide(Globenewswire)
2024-07-23 20:00
Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer(Globenewswire)
2024-07-10 20:00
Daxor Corporation's BVA-100 Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide(Globenewswire)
2024-06-17 20:00
Daxor Corporation to Showcase the Benefits of BVA-100 Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting(Globenewswire)
2024-06-04 20:00
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer(Globenewswire)
2024-04-15 20:00
New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion(Globenewswire)
2024-04-14 20:00
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100 )(Globenewswire)
2024-04-09 20:00
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital(Globenewswire)
2024-03-31 20:00
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24(Globenewswire)
2024-03-27 22:38
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-24 20:00
Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics(Globenewswire)
2024-03-21 20:00
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024(Globenewswire)
2024-03-18 02:18
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders(Globenewswire)
2024-03-18 02:18
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023(Globenewswire)
2024-03-10 20:00
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base(Globenewswire)
2024-03-07 19:00
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients(Globenewswire)
2024-02-25 19:00
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference(Globenewswire)
2024-02-11 19:00
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions(Globenewswire)
2024-02-06 19:00
Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 Blood Volume Diagnostic Across the U.S. at Existing Accounts(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.